Skip to main navigation
Cue Logo
Skip to Content
Cue Logo
  • Overview
  • News & Events
    • News Releases
    • Events and Presentations
  • Corporate Governance
    • Governance Overview
    • Management Team
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Quarterly Results
  • Stock Information
    • Stock Quote
    • Analyst Coverage
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact Investor Relations

News
Releases

Date Title
Sep 21, 2023
Cue Health Adopts Limited-Duration Shareholder Rights Plan
Aug 23, 2023
Cue Health to Present at Upcoming Investor Conferences
Aug 09, 2023
Cue Health Reports Second Quarter 2023 Financial Results
Aug 03, 2023
Cue Health Awarded New $28 Million Federal Contract to Develop Flu A/B, RSV, COVID-19 Molecular Multiplex Test for Both Over-the-Counter and Point-of-Care Use
Jul 26, 2023
Cue Health to Announce Second Quarter 2023 Financial Results
Jun 06, 2023
Cue Health Achieves Groundbreaking Milestone with FDA: First Company to Receive De Novo Authorization for a COVID-19 Home Use Test
May 31, 2023
Cue Health to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
May 10, 2023
Cue Health Reports First Quarter 2023 Financial Results
May 09, 2023
Cue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® RSV Molecular Test
May 08, 2023
Cue Health Launches Pharmacy Offering to Empower Individuals to Manage Common Health and Wellness Needs from Home

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 17

Shareholder Tools

Print Page Print Page
Email Alerts Email Alerts
RSS RSS
Contact Contact

This website contains depictions of contemplated future products and future care offerings that are still under development by Cue Health and that have not received regulatory authorization, clearance or approval. Currently, Cue Health's products authorized for commercial sale in the United States are the Cue COVID-19 Test Kit and the Cue Mpox Molecular Test Kit, both authorized under Emergency Use Authorization from the U.S. Food & Drug Administration (the “FDA”) and the COVID-19 Molecular Test Kit (De Novo granted by the FDA).

  • © 2023 Cue Health Inc. All rights reserved. Cue and the Cue logo are registered trademarks of Cue Health Inc.